Massive Hepatocellular Carcinoma with Situs Inversus Totalis Achieved a Complete Response Following Camrelizumab Plus Apatinib and Combined with Two-Stage Hepatectomy: A Case Report
Yining Wu,1,* Shenjian Ou,1,* Xiwen Liao,1,2 Chuangye Han,1,2 Chengkun Yang,1,2 Wei Qin,1 Yufeng Tan,1 Quan Lao,1 Tao Peng,1,2 Xinping Ye1 1Department of Hepatobiliary Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, 530...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2023-02-01
|
| Series: | Pharmacogenomics and Personalized Medicine |
| Subjects: | |
| Online Access: | https://www.dovepress.com/massive-hepatocellular-carcinoma-with-situs-inversus-totalis-achieved--peer-reviewed-fulltext-article-PGPM |
| _version_ | 1811169541368053760 |
|---|---|
| author | Wu Y Ou S Liao X Han C Yang C Qin W Tan Y Lao Q Peng T Ye X |
| author_facet | Wu Y Ou S Liao X Han C Yang C Qin W Tan Y Lao Q Peng T Ye X |
| author_sort | Wu Y |
| collection | DOAJ |
| description | Yining Wu,1,* Shenjian Ou,1,* Xiwen Liao,1,2 Chuangye Han,1,2 Chengkun Yang,1,2 Wei Qin,1 Yufeng Tan,1 Quan Lao,1 Tao Peng,1,2 Xinping Ye1 1Department of Hepatobiliary Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, 530021, People’s Republic of China; 2Guangxi Key Laboratory of Enhanced Recovery After Surgery for Gastrointestinal Cancer, Nanning, Guangxi Zhuang Autonomous Region, 530021, People’s Republic of China*These authors contributed equally to this workCorrespondence: Xinping Ye; Tao Peng, Tel +86-771-5356528, Fax +86-771-5350031, Email yexinping@gxmu.edu.cn; pengtaogmu@163.comAbstract: Situs inversus totalis (SIT) is a rare congenital condition in which abdominal and thoracic organs are transposed from normal positions. Two-stage hepatectomy (TSH) combined with translational therapy for hepatocellular carcinoma (HCC) with SIT has been rarely reported. We report a 41-year-old man with giant hepatocellular carcinoma (71 mm × 55 mm × 51 mm) whose future residual liver (FLR) and standard liver volume (SLV) ratio at first diagnosis was 37.4%. Preoperative volume assessment of portal vein ligation (PVL) revealed inadequate hypertrophy of FLR. After a multidisciplinary group discussion (MDT), the patient decided to follow conversion therapy. Three months later, ratio of the FLR/SLV increased from 37.4% to 71% after operation, which met the surgical requirements. Second hepatectomy, right lobectomy was successful. There was no recurrence after six months of follow-up. In our case, conversion therapy appears to be effective in maintaining residual liver hyperplasia, reducing tumor load, and preventing tumor progression in patients with large HCC during TSH.Keywords: situs inversus totalis, two-stage hepatectomy, hepatocellular carcinoma, future residual liver, multidisciplinary group discussion |
| first_indexed | 2024-04-10T16:44:13Z |
| format | Article |
| id | doaj.art-4883344f25a846daa92badc86388e0ad |
| institution | Directory Open Access Journal |
| issn | 1178-7066 |
| language | English |
| last_indexed | 2024-04-10T16:44:13Z |
| publishDate | 2023-02-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Pharmacogenomics and Personalized Medicine |
| spelling | doaj.art-4883344f25a846daa92badc86388e0ad2023-02-08T01:41:53ZengDove Medical PressPharmacogenomics and Personalized Medicine1178-70662023-02-01Volume 1611112081495Massive Hepatocellular Carcinoma with Situs Inversus Totalis Achieved a Complete Response Following Camrelizumab Plus Apatinib and Combined with Two-Stage Hepatectomy: A Case ReportWu YOu SLiao XHan CYang CQin WTan YLao QPeng TYe XYining Wu,1,* Shenjian Ou,1,* Xiwen Liao,1,2 Chuangye Han,1,2 Chengkun Yang,1,2 Wei Qin,1 Yufeng Tan,1 Quan Lao,1 Tao Peng,1,2 Xinping Ye1 1Department of Hepatobiliary Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, 530021, People’s Republic of China; 2Guangxi Key Laboratory of Enhanced Recovery After Surgery for Gastrointestinal Cancer, Nanning, Guangxi Zhuang Autonomous Region, 530021, People’s Republic of China*These authors contributed equally to this workCorrespondence: Xinping Ye; Tao Peng, Tel +86-771-5356528, Fax +86-771-5350031, Email yexinping@gxmu.edu.cn; pengtaogmu@163.comAbstract: Situs inversus totalis (SIT) is a rare congenital condition in which abdominal and thoracic organs are transposed from normal positions. Two-stage hepatectomy (TSH) combined with translational therapy for hepatocellular carcinoma (HCC) with SIT has been rarely reported. We report a 41-year-old man with giant hepatocellular carcinoma (71 mm × 55 mm × 51 mm) whose future residual liver (FLR) and standard liver volume (SLV) ratio at first diagnosis was 37.4%. Preoperative volume assessment of portal vein ligation (PVL) revealed inadequate hypertrophy of FLR. After a multidisciplinary group discussion (MDT), the patient decided to follow conversion therapy. Three months later, ratio of the FLR/SLV increased from 37.4% to 71% after operation, which met the surgical requirements. Second hepatectomy, right lobectomy was successful. There was no recurrence after six months of follow-up. In our case, conversion therapy appears to be effective in maintaining residual liver hyperplasia, reducing tumor load, and preventing tumor progression in patients with large HCC during TSH.Keywords: situs inversus totalis, two-stage hepatectomy, hepatocellular carcinoma, future residual liver, multidisciplinary group discussionhttps://www.dovepress.com/massive-hepatocellular-carcinoma-with-situs-inversus-totalis-achieved--peer-reviewed-fulltext-article-PGPMsitus inversus totalistwo-stage hepatectomyhepatocellular carcinomafuture residual livermultidisciplinary group discussion. |
| spellingShingle | Wu Y Ou S Liao X Han C Yang C Qin W Tan Y Lao Q Peng T Ye X Massive Hepatocellular Carcinoma with Situs Inversus Totalis Achieved a Complete Response Following Camrelizumab Plus Apatinib and Combined with Two-Stage Hepatectomy: A Case Report Pharmacogenomics and Personalized Medicine situs inversus totalis two-stage hepatectomy hepatocellular carcinoma future residual liver multidisciplinary group discussion. |
| title | Massive Hepatocellular Carcinoma with Situs Inversus Totalis Achieved a Complete Response Following Camrelizumab Plus Apatinib and Combined with Two-Stage Hepatectomy: A Case Report |
| title_full | Massive Hepatocellular Carcinoma with Situs Inversus Totalis Achieved a Complete Response Following Camrelizumab Plus Apatinib and Combined with Two-Stage Hepatectomy: A Case Report |
| title_fullStr | Massive Hepatocellular Carcinoma with Situs Inversus Totalis Achieved a Complete Response Following Camrelizumab Plus Apatinib and Combined with Two-Stage Hepatectomy: A Case Report |
| title_full_unstemmed | Massive Hepatocellular Carcinoma with Situs Inversus Totalis Achieved a Complete Response Following Camrelizumab Plus Apatinib and Combined with Two-Stage Hepatectomy: A Case Report |
| title_short | Massive Hepatocellular Carcinoma with Situs Inversus Totalis Achieved a Complete Response Following Camrelizumab Plus Apatinib and Combined with Two-Stage Hepatectomy: A Case Report |
| title_sort | massive hepatocellular carcinoma with situs inversus totalis achieved a complete response following camrelizumab plus apatinib and combined with two stage hepatectomy a case report |
| topic | situs inversus totalis two-stage hepatectomy hepatocellular carcinoma future residual liver multidisciplinary group discussion. |
| url | https://www.dovepress.com/massive-hepatocellular-carcinoma-with-situs-inversus-totalis-achieved--peer-reviewed-fulltext-article-PGPM |
| work_keys_str_mv | AT wuy massivehepatocellularcarcinomawithsitusinversustotalisachievedacompleteresponsefollowingcamrelizumabplusapatinibandcombinedwithtwostagehepatectomyacasereport AT ous massivehepatocellularcarcinomawithsitusinversustotalisachievedacompleteresponsefollowingcamrelizumabplusapatinibandcombinedwithtwostagehepatectomyacasereport AT liaox massivehepatocellularcarcinomawithsitusinversustotalisachievedacompleteresponsefollowingcamrelizumabplusapatinibandcombinedwithtwostagehepatectomyacasereport AT hanc massivehepatocellularcarcinomawithsitusinversustotalisachievedacompleteresponsefollowingcamrelizumabplusapatinibandcombinedwithtwostagehepatectomyacasereport AT yangc massivehepatocellularcarcinomawithsitusinversustotalisachievedacompleteresponsefollowingcamrelizumabplusapatinibandcombinedwithtwostagehepatectomyacasereport AT qinw massivehepatocellularcarcinomawithsitusinversustotalisachievedacompleteresponsefollowingcamrelizumabplusapatinibandcombinedwithtwostagehepatectomyacasereport AT tany massivehepatocellularcarcinomawithsitusinversustotalisachievedacompleteresponsefollowingcamrelizumabplusapatinibandcombinedwithtwostagehepatectomyacasereport AT laoq massivehepatocellularcarcinomawithsitusinversustotalisachievedacompleteresponsefollowingcamrelizumabplusapatinibandcombinedwithtwostagehepatectomyacasereport AT pengt massivehepatocellularcarcinomawithsitusinversustotalisachievedacompleteresponsefollowingcamrelizumabplusapatinibandcombinedwithtwostagehepatectomyacasereport AT yex massivehepatocellularcarcinomawithsitusinversustotalisachievedacompleteresponsefollowingcamrelizumabplusapatinibandcombinedwithtwostagehepatectomyacasereport |